中医肿瘤学杂志2024，Vol.6Issue(2)：42-48,7.DOI:10.19811/j.cnki.ISSN2096-6628.2024.03.006
紫龙金片联合表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的真实世界疗效分析
Real-world Efficacy Analysis of Zilongjin Tablets Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for the Treatment of Advanced Non-small Cell Lung Cancer
摘要
Abstract
Objective To observe the efficacy of Zilongjin Tablets combined with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)in the treatment of advanced non-small cell lung cancer.Methods A real-world prospective cohort study method was used.76 advanced non-small cell lung cancer patients with sensitive mutation of epidermal growth factor receptor(EGFR)gene who were treated in the Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region and the First Affiliated Hospital of Shihezi University from January 2021 to June 2022 were selected.The patients were divided into an exposure group of 35 cases and a non exposure group of 41 cases according to whether they took Zilongjin Tablets or not.In the non-exposure group,EGFR-TKIs were given until disease progression or intolerance.Zilongjin Tablets were applied to the non-exposure group for at least 8 weeks.After 8 weeks of treatment,the quality of life,physical condition,clinical symptoms,and other indicators of the two groups were compared,adverse reactions were observed,and progression free survival(PFS)was followed up.Results The mean PFS of the exposure group was significantly higher than that of the non-exposure group(14.9 months vs 12.9 months,P＜0.05).Cox regression analysis showed that the use of Zilongjin Tablets and the absence of family history of tumour were independent protective factors.In terms of EQ-5D scores representing quality of life,the exposure group had lower scores in"activity ability","daily activity",and"pain/discomfort"(P＜0.05).In terms of improvement of clinical symptoms,the improvement rates of chest tightness,fatigue and weakness in the exposure group were higher than those in the non-exposure group(P＜0.05).The ECOG score of physical condition in the exposure group significantly decreased after treatment(P＜0.05),while the decrease in the non-exposure group was not significant.The adverse reactions of the two groups were within an acceptable range,and the difference was not statistically significant(P＞0.05).Conclusion Zilongjin Tablets combined with EGFR-TKIs in the treatment of patients with advanced non-small cell lung cancer has a tendency to prolong PFS,and can improve patients'clinical symptoms and quality of life.关键词
非小细胞肺癌/真实世界研究/紫龙金片/EGFR-TKIs/生存分析Key words
non-small cell lung cancer/real-world study/Zilongjin Tablets/EGFR-TKIs/survival analysis分类
医药卫生引用本文复制引用
李朕,蔡钢,李皖豫,雷丽霞,何文婷,张洪亮..紫龙金片联合表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的真实世界疗效分析[J].中医肿瘤学杂志,2024,6(2):42-48,7.基金项目
蔡钢全国名中医传承工作室建设项目 （）
北京市中医药科技发展资金重点项目(编号:BJZYZD-2023-10). （编号:BJZYZD-2023-10）
